Granted Patent
B2
US 12,371,698 · App. 17/422,885 · Granted Jul 29, 2025
Targeted nuclear RNA cleavage and polyadenylation with CRISPR-Cas
Assignee:
University of Rochester
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides proteins, nucleic acids, systems and methods for visualizing or modulating RNA.
Claims (13)
1. A fusion protein comprising:
a) a CRISPR-associated (Cas) protein; and
b) a cleavage or polyadenylation protein,
wherein the cleavage or polyadenylation protein is NUDT21.
2. The fusion protein of claim 1 , wherein the Cas protein is catalytically dead Cas13 (dCas13).
3. The fusion protein of claim 2 , wherein dCas13 comprises a sequence selected from SEQ ID NOs: 47-48, or a variant thereof.
4. The fusion protein of claim 1 , wherein NUDT21 comprises a sequence selected from SEQ ID NOs: 51-58, or a variant thereof.
5. The fusion protein of claim 1 , wherein the fusion protein further comprises a nuclear localization signal (NLS).
6. The fusion protein of claim 5 , wherein NLS comprises a sequence selected from SEQ ID NOs: 75-695, or a variant thereof.
7. The fusion protein of claim 1 , wherein the fusion protein comprises a sequence selected from SEQ ID NOs: 696-698, or a variant thereof.
8. A nucleic acid molecule encoding the fusion protein of claim 1 .
9. A method of modulating the cleavage, polyadenylation or both of an RNA transcript in a subject, the method comprising administering to the subject: a fusion protein of claim 1 , or a nucleic acid molecule encoding the fusion protein, and a guide nucleic acid comprising a sequence complementary to a target RNA sequence in the RNA transcript.
10. The method of claim 9 being either an in vitro or in vivo method.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 16, 2025
From: ANDERSON, DOUGLAS MATTHEW
To: UNIVERSITY OF ROCHESTER
Reel/Frame 069889/0787 →
Continuity (3)
Provisional Application
62877415
· Jul 23, 2019
Provisional Application
62791971
· Jan 14, 2019
References Cited (111)
CN 110548134
· 2019
[cited by applicant]
WO 2016196655
· 2016
[cited by applicant]
WO 2017091630
· 2017
[cited by applicant]
WO 2017219027
· 2017
[cited by applicant]
WO 2018064352
· 2018
[cited by applicant]
WO 2018064371
· 2018
[cited by applicant]
WO 2018165541
· 2018
[cited by applicant]
WO 2019010422
· 2019
[cited by applicant]
WO 2019046540
· 2019
[cited by applicant]
WO 2019094969
· 2019
[cited by applicant]
WO 2019204210
· 2019
[cited by applicant]
WO 2019236982
· 2019
[cited by applicant]
WO 2019236998
· 2019
[cited by applicant]
WO 2020014261
· 2020
[cited by applicant]
WO 2020086627
· 2020
[cited by applicant]
WO 2020150287
· 2020
[cited by applicant]
WO 2021016453
· 2021
[cited by applicant]
Chaikind et al. A programmable Cas9-serine recombinase fusion protein that operates on DNA sequences in mammalian cells. Nucleic Acids Research 2016, 44;20:9758-9770. (Year: 2016).
[cited by examiner]
“RNA editing with CRISPR-Cas 13, David B T Cox et al., Science” vol. 358, No. 6366, pp. 1019-1027, Oct. 25, 2017.
[cited by applicant]
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1; clinicaltrials.gov identifier: NCT02312011; Dec. 6, 2022.
[cited by applicant]
Abudayyeh, O. O. et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, aaf5573, doi:10.1126/science.aaf5573 (2016).
[cited by applicant]
Abudayyeh, O. O. et al. RNA targeting with CRISPR-Cas13. Nature 550, 280-284, doi:10.1038/nature24049 (2017).
[cited by applicant]
Anderson, K. M. et al. Transcription of the non-coding RNA upperhand controls Hand2 expression and heart development. Nature 539, 433-436, doi:10.1038/nature20128 (2016).
[cited by applicant]
Anderson, Kelly M., et al. “Targeted cleavage and polyadenylation of RNA by CRISPR-Cas13.” BioRxiv (2019): 531111.
[cited by applicant]
Batra, Ranjan, et al. “Elimination of toxic microsatellite repeat expansion RNA by RNA-targeting Cas9.” Cell 170.5 (2017): 899-912.
[cited by applicant]
Batra, Ranjan, et al. “Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease.” Molecular cell 56.2 (2014): 311-322.
[cited by applicant]
Brook, J. David, et al. “Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member.” Cell 68.4 (1992): 799-808.
[cited by applicant]
Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340 (1997).
[cited by applicant]
Brown, M. S., Ye, J., Rawson, R. B. & Goldstein, J. L. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100, 391-398 (2000).
[cited by applicant]
Brumbaugh, J. et al. Nudt21 Controls Cell Fate by Connecting Alternative Polyadenylation to Chromatin Signaling. Cell 172, 106-120 e121, doi:10.1016/j.cell.2017.11.023 (2018).
[cited by applicant]
C. B. Gurumurthy et al., Reproducibility of CRISPR-Cas9 methods for generation of conditional mouse alleles: a multi-center evaluation. Genome Biol 20, 171 (2019).
[cited by applicant]
Carmody, S. R. & Wente, S. R. mRNA nuclear export at a glance. J Cell Sci 122, 1933-1937, doi:10.1242/jcs. 041236 (2009).
[cited by applicant]
Chan, S. L. et al. CPSF30 and Wdr33 directly bind to AAUAAA in mammalian mRNA 3′ processing. Genes & development 28, 2370-2380, doi:10.1101/gad.250993.114 (2014).
[cited by applicant]
Chang, J. W., Yeh, H. S. & Yong, J. Alternative Polyadenylation in Human Diseases. Endocrinol Metab (Seoul) 32, 413-421, doi:10.3803/EnM.2017.32.4.413 (2017).
[cited by applicant]
Chunyu Liao et al., “Modular one-pot assembly of CRISPR arrays enables library generation and reveals factors influencing crRNA biogenesis”, Nature Communications, (Jul. 3, 2019), vol. 10, No. 1, doi:10.1038/s41467-019-…
[cited by applicant]
Colgan, D. F. & Manley, J. L. Mechanism and regulation of mRNA polyadenylation. Genes Dev 11, 2755-2766 (1997).
[cited by applicant]
Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019-1027, doi:10.1126/science.aaq0180 (2017).
[cited by applicant]
Curinha, A., Oliveira Braz, S., Pereira-Castro, I., Cruz, A. & Moreira, A. Implications of polyadenylation in health and disease. Nucleus 5, 508-519, doi:10.4161/nucl.36360 (2014).
[cited by applicant]
D. Reyon et al., FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30, 460-465 (2012).
[cited by applicant]
East-Seletsky, Alexandra, et al. “RNA targeting by functionally orthogonal type VI-A CRISPR-Cas enzymes.” Molecular cell 66.3 (2017): 373-383.
[cited by applicant]
Elkon, R., Ugalde, A. P. & Agami, R. Alternative cleavage and polyadenylation: extent, regulation and function. Nat Rev Genet 14, 496-506, doi:10.1038/nrg3482 (2013).
[cited by applicant]
Engreitz, J. M. et al. Local regulation of gene expression by IncRNA promoters, transcription and splicing. Nature 539, 452-455, doi:10.1038/nature20149 (2016).
[cited by applicant]
Feng, S. et al. Improved split fluorescent proteins for endogenous protein labeling. Nature communications 8, 370, doi:10.1038/s41467-017-00494-8 (2017).
[cited by applicant]
Freije Catherine A et al, “Programmable Inhibition and Detection of RNA Viruses Using Cas13”, Molecular Cell, Elsevier, Amsterdam , NL, vol. 76, No. 5, doi: 10.1016/J.MOLCEL.2019.09.013, ISSN 1097-2765, (Oct. 10, 2019),…
[cited by applicant]
Fu, YH1, et al. “An unstable triplet repeat in a gene related to myotonic muscular dystrophy.” Science 255.5049 (1992): 1256-1258.
[cited by applicant]
Gao, Yuanzheng, et al. “Genome therapy of myotonic dystrophy type 1 iPS cells for development of autologous stem cell therapy.” Molecular Therapy 24.8 (2016): 1378-1387.
[cited by applicant]
Gao, Zongliang, Elena Herrera-Carrillo, and Ben Berkhout. “Delineation of the exact transcription termination signal for type 3 polymerase III.” Molecular Therapy—Nucleic Acids 10 (2018): 36-44.
[cited by applicant]
Guhaniyogi, J. & Brewer, G. Regulation of mRNA stability in mammalian cells. Gene 265, 11-23 (2001).
[cited by applicant]
Harley, Helen G., et al. “Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy.” American journal of human genetics 52.6 (1993): 1164.
[cited by applicant]
Higgs, D. R. et al. Alpha-thalassaemia caused by a polyadenylation signal mutation. Nature 306, 398-400 (1983).
[cited by applicant]
Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109, 1125-1131, doi:10.1172/JCI15593 (2002).
[cited by applicant]
Jauvin, Dominic, et al. “Targeting DMPK with antisense oligonucleotide improves muscle strength in myotonic dystrophy type 1 mice.” Molecular Therapy—Nucleic Acids 7 (2017): 465-474.
[cited by applicant]
Jin, Y. & Bian, T. Nontemplated nucleotide addition prior to polyadenylation: a comparison of
[cited by applicant]
Joung, J. et al. Genome-scale activation screen identifies a IncRNA locus regulating a gene neighbourhood. Nature 548, 343-346, doi:10.1038/nature23451 (2017).
[cited by applicant]
Kamiyama, D. et al. Versatile protein tagging in cells with split fluorescent protein. Nature communications 7, 11046, doi:10.1038/ncomms11046 (2016).
[cited by applicant]
Kanadia, Rahul N., et al. “A muscleblind knockout model for myotonic dystrophy.” science 302.5652 (2003): 1978-1980.
[cited by applicant]
Kanadia, Rahul N., et al. “Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly (CUG) model for myotonic dystrophy.” Proceedings of the National Academy of Sciences 103.31 (2006): 11…
[cited by applicant]
Kenna, M. A., Brachmann, C. B., Devine, S. E. & Boeke, J. D. Invading the yeast nucleus: a nuclear localization signal at the C terminus of Ty1 integrase is required for transposition in vivo. Mol Cell Biol 18, 1115-112…
[cited by applicant]
Kuyumcu-Martinez, N. Muge, and Thomas A. Cooper. “Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.” Alternative Splicing and Disease (2006): 133-159.
[cited by applicant]
L. Cong et al., Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
[cited by applicant]
Lee, Kuang-Yung, et al. “Compound loss of muscleblind-like function in myotonic dystrophy.” EYadava et al., Hum Geet, 2019MBO molecular medicine 5.12 (2013): 1887-1900.
[cited by applicant]
Levitt, N., Briggs, D., Gil, A. & Proudfoot, N. J. Definition of an efficient synthetic poly(A) site. Genes & development 3, 1019-1025 (1989).
[cited by applicant]
Li Lin et al., “Engineering the Direct Repeat Sequence of crRNA for Optimization of FnCpf1-Mediated Genome Editing in Human Cells”, Molecular Therapy, Nov. 2018, vol. 26, No. 11, p. 2650-2657, DOI: 10.1016/j.ymthe.2018.…
[cited by applicant]
Mahadevan, Mani, et al. “Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene.” Science 255.5049 (1992): 1253-1255.
[cited by applicant]
Mandel, C. R., Bai, Y. & Tong, L. Protein factors in pre-mRNA 3′-end processing. Cell Mol Life Sci 65, 1099-1122, doi:10.1007/s00018-007-7474-3 (2008).
[cited by applicant]
Mankodi, Ami, et al. “Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.” Human molecular genetics 10.19 (2001): 2165-2170.
[cited by applicant]
Mankodi, Ami, et al. “Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.” Science 289.5485 (2000): 1769-1772.
[cited by applicant]
Martorell, L., et al. “Frequency and stability of the myotonic dystrophy type 1 premutation.” Neurology 56.3 (2001): 328-335.
[cited by applicant]
McLane, L. M., Pulliam, K. F., Devine, S. E. & Corbett, A. H. The Ty1 integrase protein can exploit the classical nuclear protein import machinery for entry into the nucleus. Nucleic Acids Res 36, 4317-4326, doi:10.1093…
[cited by applicant]
Michael P Robertson et al, “The Structure of a Rigorously Conserved RNA Element within the SARS Virus Genome”, PLOS Biology, (Dec. 28, 2004), vol. 3, No. 1, doi:10.1371/journal.pbio.0030005, p. e5, XP055734415.
[cited by applicant]
Nakamori, Masayuki, et al. “Splicing biomarkers of disease severity in myotonic dystrophy.” Annals of neurology 74.6 (2013): 862-872.
[cited by applicant]
Napierala, Marek, and Wlodzimierz J. Krzyzosiak. “CUG repeats present in myotonin kinase RNA form metastable “slippery” hairpins.” Journal of Biological Chemistry 272.49 (1997): 31079-31085.
[cited by applicant]
Nguyen Tuan M et al, “Virus against virus: a potential treatment for 2019-nCov (SARS-COV-2) and other RNA viruses”, Cell Research, Nature Publishing Group, GB, CN, vol. 30, No. 3, doi:10.1038/S41422-020-0290-0, ISSN 100…
[cited by applicant]
O'Brien, K., Matlin, A. J., Lowell, A. M. & Moore, M. J. The biflavonoid isoginkgetin is a general inhibitor of Pre-mRNA splicing. The Journal of biological chemistry 283, 33147-33154, doi:10.1074/jbc.M805556200 (2008).
[cited by applicant]
O'Connell, M. R. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems. J Mol Biol 431, 66-87, doi:10.1016/j.jmb.2018.06.029 (2019).
[cited by applicant]
Orkin, S. H., Cheng, T. C., Antonarakis, S. E. & Kazazian, H. H., Jr. Thalassemia due to a mutation in the cleavage-polyadenylation signal of the human beta-globin gene. The EMBO journal 4, 453-456 (1985).
[cited by applicant]
Pedelacq, J. D., Cabantous, S., Tran, T., Terwilliger, T. C. & Waldo, G. S. Engineering and characterization of a superfolder green fluorescent protein. Nat Biotechnol 24, 79-88, doi:10.1038/nbt1172 (2006).
[cited by applicant]
Poosala P, Lindley SR, Anderson KM, and Anderson DM. 2019. Targeting Toxic Nuclear RNA Foci with CRISPR-Cas13 to Treat Myotonic Dystrophy bioRxiv doi:10.1101/716514.
[cited by applicant]
Rinn, J. L. & Chang, H. Y. Genome regulation by long noncoding RNAs. Annu Rev Biochem 81, 145-166, doi:10.1146/annurev-biochem-051410-092902 (2012).
[cited by applicant]
Rund, D. et al. Two mutations in the beta-globin polyadenylylation signal reveal extended transcripts and new RNA polyadenylylation sites. Proceedings of the National Academy of Sciences of the United States of America …
[cited by applicant]
S. P. Moore, L. A. Rinckel, D. J. Garfinkel, A Ty1 integrase nuclear localization signal required for retrotransposition. Mol Cell Biol 18, 1105-1114 (1998).
[cited by applicant]
S. Pellenz et al., New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion. Hum Gene Ther 30, 814-828 (2019).
[cited by applicant]
Sartini, B. L., Wang, H., Wang, W., Millette, C. F. & Kilpatrick, D. L. Pre-messenger RNA cleavage factor I (CFIm): potential role in alternative polyadenylation during spermatogenesis. Biol Reprod 78, 472-482, doi:10.1…
[cited by applicant]
Shimazu, Tadahiro, Sueharu Horinouchi, and Minoru Yoshida. “Multiple histone deacetylases and the CREB-binding protein regulate pre-mRNA ′-end processing.” Journal of Biological Chemistry 282.7 (2007): 4470-4478.
[cited by applicant]
Smargon, Aaron A., et al. “Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28.” Molecular cell 65.4 (2017): 618-630.
[cited by applicant]
T Li et al., “siRNA targeting the Leader sequence of SARS-COV inhibits virus replication”, Gene Therapy, GB, (Mar. 17, 2005), vol. 12, No. 9, doi:10.1038/sj.gt.3302479, ISSN 0969-7128, pp. 751-761, XP055734417.
[cited by applicant]
Taneja, Krishan L., et al. “Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.” The Journal of cell biology 128.6 (1995): 995-1002.
[cited by applicant]
Thornton, Charles A., Eric Wang, and Ellie M. Carrell. “Myotonic dystrophy: approach to therapy.” Current opinion in genetics & development 44 (2017): 135-140.
[cited by applicant]
Tian, B. & Graber, J. H. Signals for pre-mRNA cleavage and polyadenylation. Wiley Interdiscip Rev RNA 3, 385-396, doi:10.1002/wrna. 116 (2012).
[cited by applicant]
Tian, B. & Manley, J. L. Alternative polyadenylation of mRNA precursors. Nat Rev Mol Cell Biol 18, 18-30, doi:10.1038/nrm.2016.116 (2017).
[cited by applicant]
Tian, B. I. N., et al. “Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR.” RNA 6.1 (2000): 79-87.
[cited by applicant]
Timothy R Abbott et al., “Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza”, BIORXIV, (Mar. 14, 2020), doi:10.1101/2020.03.13.991307, XP055733410.
[cited by applicant]
Van Agtmaal, Ellen L., et al. “CRISPR/Cas9-induced (CTG · CAG) n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing.” Molecular therapy 25.1 (2017): 24-43.
[cited by applicant]
Venkataraman, K., Brown, K. M. & Gilmartin, G. M. Analysis of a noncanonical poly(A) site reveals a tripartite mechanism for vertebrate poly(A) site recognition. Genes & development 19, 1315-1327, doi:10.1101/gad. 12986…
[cited by applicant]
Wang, Yanlin, et al. “Therapeutic genome editing for myotonic dystrophy type 1 using CRISPR/Cas9.” Molecular Therapy 26.11 (2018): 2617-2630.
[cited by applicant]
Wheeler, Thurman M., et al. “Correction of CIC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy.” The Journal of clinical investigation 117.12 (2007): 3952-3957.
[cited by applicant]
Wheeler, Thurman M., et al. “Targeting nuclear RNA for in vivo correction of myotonic dystrophy.” Nature 488.7409 (2012): 111-115.
[cited by applicant]
Wu, X. & Brewer, G. The regulation of mRNA stability in mammalian cells: 2.0. Gene 500, 10-21, doi:10.1016/j.gene.2012.03.021 (2012).
[cited by applicant]
Xiang, K., Tong, L. & Manley, J. L. Delineating the structural blueprint of the pre-mRNA 3′-end processing machinery. Molecular and cellular biology 34, 1894-1910, doi:10.1128/MCB.00084-14 (2014).
[cited by applicant]
Yadava, Ramesh S., et al. “MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity.” Human molecular genetics 28.14 (2019): 2330-2338.
[cited by applicant]
Yang, Qin, et al. “Crystal structure of a human cleavage factor CFIm25/CFIm68/RNA complex provides an insight into poly (A) site recognition and RNA looping.” Structure 19.3 (2011): 368-377.
[cited by applicant]
Yang, Qin, Gregory M. Gilmartin, and Sylvie Doublié. “Structural basis of UGUA recognition by the Nudix protein CFlm25 and implications for a regulatory role in mRNA 3′ processing.” Proceedings of the National Academy o…
[cited by applicant]
Ying Dang et al., “Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency”, Genome Biology, (Jan. 1, 2015), vol. 16, No. 280, doi:10.1186/s13059-015-0846-3, pp. 1-10, XP055369116.
[cited by applicant]
Zahir Ali et al, “CRISPR/Cas13 as a Tool for RNA Interference”, Trends in Plant Science, GB, (Mar. 28, 2018), vol. 23, No. 5, doi:10.1016/j.tplants.2018.03.003, ISSN 1360-1385, pp. 374-378, XP055680754.
[cited by applicant]
Zhao, J., Hyman, L. & Moore, C. Formation of mRNA 3′ ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev 63, 405-445 (1999).
[cited by applicant]
Zhu, Y. et al. Molecular Mechanisms for CFlm-Mediated Regulation of mRNA Alternative Polyadenylation. Molecular cell 69, 62-74 e64, doi: 10.1016/j.molcel.2017.11.031 (2018).
[cited by applicant]
Zu, Tao, et al. “Non-ATG-initiated translation directed by microsatellite expansions.” Proceedings of the National Academy of Sciences 108.1 (2011): 260-265.
[cited by applicant]